Triveni Bio raised $115M in a Series B funding round led by Goldman Sachs Alternatives to advance its novel antibody treatments for immunological disorders.
Amount Raised
$115 Million
Round Type
Series B
WalthamBiotechnologyHealth CareInvestors
Description
Triveni Bio, a Watertown, MA-based biotech company, has successfully raised $115M in Series B financing. The funds will support the advancement of its second-generation anti-kallikrein treatments through clinical proof-of-concept.
Quick answer
Triveni Bio raised $115 Million in a Series B round, dated October 2, 2024. Investors: Viking Global Investors, Atlas Venture, Cormorant Asset Management, Fidelity Management & Research Company, Deep Track Capital, Invus, Goldman Sachs Alternatives and Orbimed. Triveni Bio is based in Waltham, Massachusetts, United States.
- How much did Triveni Bio raise?
- Triveni Bio raised $115 Million in a Series B round on October 2, 2024.
- Who invested in Triveni Bio?
- Viking Global Investors, Atlas Venture, Cormorant Asset Management, Fidelity Management & Research Company, Deep Track Capital, Invus, Goldman Sachs Alternatives and Orbimed are named as investors in this round.
- What does Triveni Bio do?
- Triveni Bio is a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders.
- Where is Triveni Bio based and how big is it?
- Triveni Bio is based in Waltham, Massachusetts, United States.
- Who are the decision-makers at Triveni Bio?
- Fundz holds 2 contacts at Triveni Bio, including the Chief Medical Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Triveni Bio that raised within 45 days of this round, from Fundz verified event records.
- FOXO Technologies raised $220K on November 15, 2024.
- EMBIO Diagnostics raised $2.6M (Seed) on November 15, 2024.
- Naturbeads raised $9.9M (Series A) on November 14, 2024.
- Metsera raised $215M (Series B) on November 13, 2024.
- Prelude raised $8.1M (Seed) on November 13, 2024.
- OrthoPulse raised $4.5M (Seed) on November 13, 2024.
Who to call at Triveni Bio, and when
A new round usually means Triveni Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Triveni Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Triveni Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Triveni Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Triveni Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTriveni Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.